NEXMED

Reducing your GLP-1 dose: how to talk to your doctor

Legitimate reasons for a lower dose, what to prepare before your appointment and the questions to ask your doctor.

Nexmed Editorial · Updated 30 September 2026
Reducing your GLP-1 dose: how to talk to your doctor

Are you thinking about a lower dose of Wegovy, Mounjaro or Ozempic? Maybe because of side effects, cost, or because you've reached your target weight. It's a legitimate question, supported by trials and by the prescribing information. Here's how to raise it with your doctor so you can make the best decision together.

In short: the prescribing information allows staying on a lower dose if the higher one isn't tolerated, and a 2026 trial shows that lowering the dose after weight loss can preserve a large part of the result. Prepare your data (weight, side effects, goals), ask concrete questions, and don't change the dose on your own.

Legitimate reasons to discuss a lower dose

  • Side effects that don't go away: nausea, vomiting, constipation or loss of appetite that affects your daily life (see how to manage them). In such situations, the Wegovy prescribing information recommends delaying the dose increase or going back to the previous dose.
  • You've reached your target weight: you're entering the maintenance phase, where the goal changes.
  • You're losing weight well on your current dose: increasing the dose isn't mandatory if the result is already good.
  • Cost: obesity medicines are often not covered by insurance, and higher doses can cost more.

What the trials say, briefly

  • A lower dose has a real effect, but a smaller one on average. In SURMOUNT-1, tirzepatide 5 mg led to −15.0%, versus −20.9% on 15 mg. In STEP 2, semaglutide 1.0 mg led to −7.0%, versus −9.6% on 2.4 mg (in patients with diabetes).
  • Lowering the dose after weight loss has been tested. In SURMOUNT-MAINTAIN (2026), patients switched from the maximum dose to tirzepatide 5 mg ended at −16.6%, versus −21.9% on the full dose and −9.9% on placebo.
  • Stopping abruptly is the riskiest option. After stopping treatment, most patients regain a large part of the weight.

Details in our article on the minimum effective dose.

What to prepare before your appointment

1. Your weight trend. Write down your weight (ideally the weekly average), your waist circumference and how they have changed since you started treatment.

2. Side effects. What you feel, how often, how long it lasts after the injection and how much it affects you.

3. Your goal. Do you want to lose more or maintain? What weight are you aiming for?

4. Other medicines and conditions. Especially insulin or sulfonylureas (for diabetes), oral contraceptives (if you take Mounjaro), any new condition, and whether you're planning a pregnancy (see GLP-1 and fertility).

5. Recent lab tests, if you have them: blood sugar, HbA1c, cholesterol, kidney function.

Questions to ask your doctor

  1. Based on how I'm doing, what dose do you think is right for me now?
  2. What result can I expect if I stay on my current dose or lower it?
  3. If we lower the dose, how will we track whether my weight starts to go up? How often should I come back for check-ups?
  4. What do we do if I regain weight?
  5. Could my side effects improve on a lower dose?
  6. Do other medicines need adjusting if we change my dose?
  7. How long should I continue treatment?

What NOT to do

  • Don't lower the dose on your own, by guesswork or by "counting clicks" on the pen. Pens are calibrated for fixed doses. See why improvised doses are dangerous.
  • Don't buy "microdoses" online. These products are not regulated, and microdosing has no trials behind it. See what's real about microdosing.
  • Don't stop treatment abruptly without a plan, if your goal is to maintain your weight.
  • Don't compare yourself to others. Response to treatment is individual.

After the dose change

  • weigh yourself regularly and record the weekly average;
  • keep eating enough protein and stay physically active, especially with strength training;
  • go to your scheduled check-ups;
  • tell your doctor if your weight keeps rising or if new side effects appear.

Bring data to the appointment: a GLP-1 tracker app such as Reko (partner app, iPhone) shows your doses, weight, side effects and protein intake over time.

Conclusion

Asking for a lower dose is not a sign of "failure", nor an attempt to cut treatment short. It's a legitimate medical question, supported by trials and by the prescribing information. With your data prepared and the right questions, you and your doctor can make a decision that keeps your result with as few side effects as possible.

Frequently asked questions

Can I ask my doctor for a lower dose of Wegovy or Mounjaro? Yes. The prescribing information allows staying on a lower dose if the higher one isn't tolerated, and for Mounjaro, 5 mg is an official maintenance dose.

What should I bring to the appointment? Your weight and waist trend, a list of side effects, your goal, your other medicines and recent lab tests.

If I lower the dose, will I lose everything I've lost? Not necessarily. In SURMOUNT-MAINTAIN, patients switched to 5 mg kept a large part of the result, though less than on the full dose. Regular monitoring is essential.

Can I go straight from the high dose to the low one? How the dose is changed is decided by your doctor.

Does lowering the dose reduce side effects? Gastrointestinal effects are often more common at higher doses. In STEP 2, gastrointestinal effects occurred in 57.5% of patients on semaglutide 1.0 mg, versus 63.5% on 2.4 mg.

Read also

Useful calculators

Before your appointment, these can help you prepare your data:

The "GLP-1 dose" series

  1. The minimum effective GLP-1 dose: do you need the maximum dose?
  2. Mounjaro 5 mg vs 10 mg vs 15 mg: what the trials show
  3. Lowering the dose after weight loss: the SURMOUNT-MAINTAIN trial
  4. GLP-1 microdosing: what's real and what's marketing
  5. Ozempic overdose: why you shouldn't calculate your own dose
  6. Reducing your GLP-1 dose: how to talk to your doctor

Sources

  • Jastreboff AM et al. SURMOUNT-1. N Engl J Med. 2022;387:205-216. doi:10.1056/NEJMoa2206038
  • Davies M et al. STEP 2. Lancet. 2021;397:971-984. doi:10.1016/S0140-6736(21)00213-0
  • SURMOUNT-MAINTAIN. Lancet. 2026;407:2305-2318. doi:10.1016/S0140-6736(26)00656-2
  • Summary of Product Characteristics (SmPC): Wegovy, Mounjaro (European Medicines Agency).

Educational content, updated September 2026. It does not replace medical advice. Do not change the dose, frequency or way you take a medicine without the agreement of the doctor who prescribed it.

This article is for general information only and does not replace advice from your doctor or pharmacist. Do not start, stop or change a treatment without medical supervision.

More on weight loss & GLP-1